Demographic data and prescribing patterns among patients with VWD and AF alone, ACS alone, and both AF and ACS
| . | AF alone (n = 62) . | ACS alone (n = 28) . | AF and ACS (n = 27) . |
|---|---|---|---|
| Demographic data | |||
| Age, median (IQR), y | 64.1 (52.0-73.6) | 59.5 (55.5-68.1) | 66.9 (59.6-74.3) |
| Sex, female, n (%) | 45 (72.6%) | 14 (50.0%) | 12 (44.4%) |
| Deceased, n (%) | 13 (21.0%) | 10 (35.7%) | 10 (37.0%) |
| Diabetes, n (%) | 12 (19.4%) | 11 (39.3%) | 13 (48.1%) |
| HTN, n (%) | 53 (85.5%) | 27 (96.4%) | 27 (100.0%) |
| CHF, n (%) | 26 (41.9%) | 13 (46.4%) | 23 (85.2%) |
| Smoking, n (%) | 16 (25.8%) | 8 (28.6%) | 10 (37.0%) |
| CHA2DS2-VASC score, median (IQR) | 3 (2-4) | — | 5 (4-6) |
| PCI, n (%) | — | 10 (35.7%) | 10 (37.0%) |
| CABG, n (%) | — | 3 (10.7%) | 10 (37.0%) |
| Ever prescribed,n (%) | |||
| Aspirin | 17 (27.4%) | 21 (75.0%) | 20 (74.1%) |
| P2Y12 inhibitor | 1 (1.6%) | 12 (42.9%) | 11 (40.7%) |
| DAPT | — | 11 (39.3%) | 10 (37.0%) |
| AC | 38 (61.3%) | 1 (3.6%) | 12 (44.4%) |
| No AC or AP | 18 (29.0%) | 6 (21.4%) | 3 (11.1%) |
| Duration of use, median (IQR), y | |||
| Aspirin | 8.6 (0.8-11.7) | 6.2 (3.4-17.0) | 13.0 (8.7-15.7) |
| DAPT | — | 0.1 (0.1-0.1) | 1.2 (0.1-9.0) |
| AC | 2.7 (1.5-8.6) | — | 8.4 (2.7-13.2) |
| . | AF alone (n = 62) . | ACS alone (n = 28) . | AF and ACS (n = 27) . |
|---|---|---|---|
| Demographic data | |||
| Age, median (IQR), y | 64.1 (52.0-73.6) | 59.5 (55.5-68.1) | 66.9 (59.6-74.3) |
| Sex, female, n (%) | 45 (72.6%) | 14 (50.0%) | 12 (44.4%) |
| Deceased, n (%) | 13 (21.0%) | 10 (35.7%) | 10 (37.0%) |
| Diabetes, n (%) | 12 (19.4%) | 11 (39.3%) | 13 (48.1%) |
| HTN, n (%) | 53 (85.5%) | 27 (96.4%) | 27 (100.0%) |
| CHF, n (%) | 26 (41.9%) | 13 (46.4%) | 23 (85.2%) |
| Smoking, n (%) | 16 (25.8%) | 8 (28.6%) | 10 (37.0%) |
| CHA2DS2-VASC score, median (IQR) | 3 (2-4) | — | 5 (4-6) |
| PCI, n (%) | — | 10 (35.7%) | 10 (37.0%) |
| CABG, n (%) | — | 3 (10.7%) | 10 (37.0%) |
| Ever prescribed,n (%) | |||
| Aspirin | 17 (27.4%) | 21 (75.0%) | 20 (74.1%) |
| P2Y12 inhibitor | 1 (1.6%) | 12 (42.9%) | 11 (40.7%) |
| DAPT | — | 11 (39.3%) | 10 (37.0%) |
| AC | 38 (61.3%) | 1 (3.6%) | 12 (44.4%) |
| No AC or AP | 18 (29.0%) | 6 (21.4%) | 3 (11.1%) |
| Duration of use, median (IQR), y | |||
| Aspirin | 8.6 (0.8-11.7) | 6.2 (3.4-17.0) | 13.0 (8.7-15.7) |
| DAPT | — | 0.1 (0.1-0.1) | 1.2 (0.1-9.0) |
| AC | 2.7 (1.5-8.6) | — | 8.4 (2.7-13.2) |
Each column represents a cohort that is assessed separately (AF alone, ACS alone, and both AF and ACS). The percentages in the table indicate the proportion of each cohort who had a given condition or medication use. Thus, the percentages do not add to 100% across a given row.
AC, anticoagulation; AP, antiplatelet agent; CABG, coronary artery bypass grafting; CHF, congestive heart failure; HTN, hypertension; IQR, interquartile range.